Purple Biotech executive details share and option holdings
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares.
Rhea-AI Filing Summary
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Schickler Michael
Role
Head of Clinical & Reg Affairs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,051,000 contracts (Direct);
Ordinary Shares — 9,254,472 shares (Direct)
Footnotes (5)
- F1. Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
- F2. Represents stock option to purchase 151,000 Ordinary Shares (equivalent to 76 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.10828125 per Ordinary Share and the option expires on April 2, 2027.
- F3. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.
- F4. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 393,750 Ordinary Shares are vested and exercisable, with the remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027.The exercise price of this stock option is $0.0115625 per Ordinary Share and the option expires on August 15, 2029.
- F5. Represents stock option to purchase 7,100,000 Ordinary Shares (equivalent to 3,550 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 591,666 Ordinary Shares are vested and exercisable, with the remaining options to purchase 6,508,334 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030
Key Figures
Ordinary Shares held: 9,254,472 Ordinary Shares
Unvested RSUs: 6,958,334 RSUs
ADS ratio: 2,000 Ordinary Shares per ADS
+4 more
7 metrics
Ordinary Shares held
9,254,472 Ordinary Shares
Total beneficial ownership reported on Form 3
Unvested RSUs
6,958,334 RSUs
Each RSU for one Ordinary Share, time-based vesting
ADS ratio
2,000 Ordinary Shares per ADS
Ordinary Shares may be represented by ADSs
Option grant 1
151,000 shares at $0.10828125
Exercise price per Ordinary Share, expires April 2, 2027
Option grant 2
900,000 shares at $0.095054688
Exercise price per Ordinary Share, expires May 23, 2027
Option grant 3 vesting
393,750 vested / 506,250 unvested of 900,000
Vests quarterly until August 14, 2027 at $0.0115625, expires August 15, 2029
Option grant 4 vesting
591,666 vested / 6,508,334 unvested of 7,100,000
Vests quarterly until October 21, 2028 at $0.00309375, expires October 21, 2030
Key Terms
restricted stock units ("RSUs"), American Depositary Shares, exercise price, vesting in equal quarterly installments, +1 more
5 terms
restricted stock units ("RSUs") financial
"Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
exercise price financial
"The exercise price of this stock option is $0.10828125 per Ordinary Share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting in equal quarterly installments financial
"remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027"
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Michael Schickler report owning in Purple Biotech (PPBT)?
He reports beneficial ownership of 9,254,472 Ordinary Shares of Purple Biotech. This figure includes both already-issued shares and a large block of unvested RSUs that will settle in Ordinary Shares as time-based vesting conditions are met.
How many unvested RSUs does the Purple Biotech (PPBT) executive hold?
He holds 6,958,334 unvested restricted stock units (RSUs), each representing one Ordinary Share. These RSUs vest over time based on service conditions and are settled in Ordinary Shares, which may be represented by American Depositary Shares.
When do Michael Schickler’s Purple Biotech (PPBT) stock options expire?
His reported stock options expire on April 2, 2027, May 23, 2027, August 15, 2029, and October 21, 2030. These expirations apply to different option grants, each with its own exercise price and vesting schedule.
What is the ADS ratio for Purple Biotech (PPBT) in this filing?
Each American Depositary Share (ADS) currently represents 2,000 Ordinary Shares of Purple Biotech. This means the equity awards and holdings reported in Ordinary Shares could also be represented in ADS form using that 2,000-to-1 ratio.
AI-generated analysis. How Rhea-AI works. Not financial advice.
